[go: up one dir, main page]

MX2012007548A - Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos. - Google Patents

Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos.

Info

Publication number
MX2012007548A
MX2012007548A MX2012007548A MX2012007548A MX2012007548A MX 2012007548 A MX2012007548 A MX 2012007548A MX 2012007548 A MX2012007548 A MX 2012007548A MX 2012007548 A MX2012007548 A MX 2012007548A MX 2012007548 A MX2012007548 A MX 2012007548A
Authority
MX
Mexico
Prior art keywords
ampk
activators
pyridinedione
thieno
therapeutic uses
Prior art date
Application number
MX2012007548A
Other languages
English (en)
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Christine Charon
Franck Lepifre
Sebastien Bolze
Laurent Faveriel
Jean-Denis Durand
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of MX2012007548A publication Critical patent/MX2012007548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos que son activadores directos de AMPK (Proteína quinasa activada con AMP) y su uso en el tratamiento de trastornos regulados por la activación de AMPK. Por ejemplo, compuestos de acuerdo con la invención son útiles para el tratamiento de diabetes, síndrome metabólico, obesidad, inflamación, cáncer y enfermedades cardiovasculares.
MX2012007548A 2009-12-29 2010-12-28 Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos. MX2012007548A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306344 2009-12-29
PCT/EP2010/070811 WO2011080277A1 (en) 2009-12-29 2010-12-28 Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2012007548A true MX2012007548A (es) 2012-07-23

Family

ID=41691577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007548A MX2012007548A (es) 2009-12-29 2010-12-28 Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos.

Country Status (24)

Country Link
US (1) US9365584B2 (es)
EP (1) EP2519527B1 (es)
JP (1) JP5559894B2 (es)
KR (1) KR101469002B1 (es)
CN (1) CN102803269B (es)
AU (1) AU2010338280B2 (es)
BR (1) BR112012016330B8 (es)
CA (1) CA2784553C (es)
CY (1) CY1114952T1 (es)
DK (1) DK2519527T3 (es)
EA (1) EA020588B1 (es)
ES (1) ES2445537T3 (es)
HR (1) HRP20140035T1 (es)
IL (1) IL220432A (es)
ME (1) ME01558B (es)
MX (1) MX2012007548A (es)
PL (1) PL2519527T3 (es)
PT (1) PT2519527E (es)
RS (1) RS53282B (es)
SI (1) SI2519527T1 (es)
SM (1) SMT201400013B (es)
TW (1) TWI574968B (es)
WO (1) WO2011080277A1 (es)
ZA (1) ZA201205604B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123760C2 (uk) 2011-11-11 2021-06-02 Гіліад Аполло, Ллс Сполука (варіанти) та композиція, що містить сполуку
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
WO2017011917A1 (en) * 2015-07-23 2017-01-26 Thrasos Therapeutics Inc. Methods for treating and preventing polycystic kidney diseases (pkd) using amp-activated protein kinase (ampk) modulators and activators
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
KR20180082556A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 피라졸 acc 억제제 및 그의 용도
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
EP3379933B1 (en) 2015-11-25 2023-02-15 Gilead Apollo, LLC Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
ES2939977T3 (es) 2015-11-25 2023-04-28 Gilead Apollo Llc Inhibidores de triazol ACC y usos de los mismos
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
TWI680122B (zh) * 2016-09-07 2019-12-21 國立陽明大學 活化腺苷單磷酸活化蛋白激酶之化合物
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2023092094A2 (en) 2021-11-19 2023-05-25 The Broad Institute, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
NZ589136A (en) * 2008-04-11 2012-06-29 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Also Published As

Publication number Publication date
KR101469002B1 (ko) 2014-12-04
EA201200975A1 (ru) 2012-12-28
RS53282B (sr) 2014-08-29
US20130053401A1 (en) 2013-02-28
AU2010338280A1 (en) 2012-07-26
SMT201400013B (it) 2014-05-07
SI2519527T1 (sl) 2014-06-30
CN102803269A (zh) 2012-11-28
BR112012016330A2 (pt) 2018-04-03
CN102803269B (zh) 2016-01-13
IL220432A (en) 2015-02-26
EP2519527B1 (en) 2013-12-18
ES2445537T3 (es) 2014-03-03
ME01558B (me) 2014-04-20
TWI574968B (zh) 2017-03-21
HRP20140035T1 (hr) 2014-02-14
BR112012016330B1 (pt) 2021-03-23
JP2013515758A (ja) 2013-05-09
US9365584B2 (en) 2016-06-14
CA2784553C (en) 2014-08-19
PT2519527E (pt) 2014-02-17
WO2011080277A1 (en) 2011-07-07
PL2519527T3 (pl) 2014-06-30
JP5559894B2 (ja) 2014-07-23
ZA201205604B (en) 2013-05-29
EP2519527A1 (en) 2012-11-07
DK2519527T3 (da) 2014-01-27
KR20120120232A (ko) 2012-11-01
BR112012016330B8 (pt) 2021-05-25
AU2010338280B2 (en) 2013-08-22
EA020588B1 (ru) 2014-12-30
CY1114952T1 (el) 2016-12-14
TW201144318A (en) 2011-12-16
CA2784553A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
MX2012007548A (es) Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos.
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
PH12015501806B1 (en) Novel benzopyran kinase modulators
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
CL2007001165A1 (es) 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
UA115887C2 (uk) АМІНОЗАМІЩЕНІ ІМІДАЗО[1,2-а]ПІРИДИНКАРБОКСАМІДИ І ЇХ ЗАСТОСУВАННЯ
AU2008317057A8 (en) Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
PH12013500055A1 (en) Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
WO2011041399A3 (en) Pi3k (delta) selective inhibitors
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IN2012DN02081A (es)
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
CL2011000118A1 (es) Compuestos derivados de imidazo[1,2-a]pirimidina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso como inhibidores de quinasa para tratar cancer, trastornos metabolicos, alegis, asmas, trombosis, retonipatias, psoriasis, artritis reumatoide, diabetes, degeneracion muscular.
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
MY150931A (en) Substituted oxazolidinones and their use
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL200570A0 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders

Legal Events

Date Code Title Description
FG Grant or registration